Completed and pending initial public offerings by biopharma companies, including: 4D Molecular, Akeso, Beam, Bio-Thera, Continent, Frontier, Hutchison China Meditech, Imara, Immunotech, Innocare, NLS, Oric, Passage Bio, Revolution Medicines, Scilex, Shanghai Shenlian, Tasly.